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Abstract
Background: Aquaporins (AQPs) have been recognized to promote tumor progression, invasion, and metastasis
and are therefore recognized as promising targets for novel anti-cancer therapies. Potentially relevant AQPs in
distinct cancer entities can be determined by a comprehensive expression analysis of the 13 human AQPs.
Methods: We analyzed the presence of all AQP transcripts in 576 different normal lung and non-small cell lung
cancer (NSCLC) samples using microarray data and validated our findings by qRT-PCR and immunohistochemistry.
Results: Variable expression of several AQPs (AQP1, -3, -4, and -5) was found in NSCLC and normal lung tissues.
Furthermore, we identified remarkable differences between NSCLC subtypes in regard to AQP1, -3 and -4
expression. Higher transcript and protein levels of AQP4 in well-differentiated lung adenocarcinomas suggested an
association with a more favourable prognosis. Beyond water transport, data mining of co-expressed genes
indicated an involvement of AQP4 in cell-cell signalling, cellular movement and lipid metabolism, and underlined
the association of AQP4 to important physiological functions in benign lung tissue.
Conclusions: Our findings accentuate the need to identify functional differences and redundancies of active AQPs
in normal and tumor cells in order to assess their value as promising drug targets.
Background
The human body consists of about 70% water and the reg-
ulation of water and thus ion homeostasis is a basic cell
function. The assumption of water freely crossing cell
membranes by pure diffusion was changed by detection of
water-selective channels which are now known as aqua-
porins (AQPs). Selective water transport is essential to
maintain the cellular electrochemical potential. In mam-
mals, 13 members of the aquaporin gene family (AQP0
through AQP12) have been identified [1]. AQPs have been
found to play a pro-tumorigenic role in different tumor
types. Besides the transport of water across biological
membranes as their main role in normal cells, AQP-
expressing cancer cells show enhanced migration in vitro,
and increased invasiveness, extravasation, and potential to
metastasize in vivo [2]. In contrast to the pro-tumorigenic
function caused by enhanced AQP expression in some
tumors, reduced expression of AQPs in hepatocellular
carcinoma is associated with increased resistance to apop-
tosis [3]. However, the pro-tumorigenic and/or anti-
apoptotic functions of AQPs are poorly understood.
Recently, first data demonstrated the potential usage of
AQP inhibition in anti-cancer therapies also in humans
[4]. Current theories associate AQP activity with osmotic
pressure increase to form cell protrusions essential for
migration while aquaglyceroporins may play a key role in
tumor energy metabolism [2,5-8]. A further, yet not suffi-
ciently considered possibility for pro-tumorigenic func-
tions of AQPs is the direct or indirect regulation of other
genes, for example stabilization of hypoxia-inducible fac-
tor, which is facilitated by AQP1 expression [9] or the
interaction of AQP5 with the Ras/extracellular signal-
regulated kinase/retinoblastoma protein signaling pathway
[10]. Since AQPs have been recognized as promising tar-
gets for novel anti-cancer therapies [11,12], it is important
to elucidate their tumor-specific expression patterns and
to reveal their potential functions besides sole water trans-
port in the different organs and tumor entities.
In the present study, we focused on non-small cell
lung cancer (NSCLC), the most common malignant
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lung tumor, in particular its two major histological sub-
types, adenocarcinoma (AC) and squamous cell carci-
noma (SCC). In normal human lungs expression of
AQP1, -3, -4, and -5 has been described [13]. Only little
is known about the expression of AQPs in NSCLCs:
AQP1 is expressed in AC [14,15] and it was shown that
AQP1 expression facilitated tumor cell migration and
spread whereas AQP1 inhibition reduced the metastatic
potential of tumor cells [16]. AQP3 is also expressed in
NSCLCs but more prominent in AC than in SCC [17].
The expression of AQP4 and the potential roles of both
AQP3 and AQP4 in lung carcinogenesis are unknown.
Overexpression of AQP5 has most recently been
reported to promote tumor invasion of human NSCLCs
[18,19]. In order to get more insight into the expression
patterns of AQPs in human NSCLCs, its relations to
patient survival and to other cellular processes besides
water transport and to provide a basis for further func-
tional characterization we analyzed independent micro-
array studies and validated the expression of the most
prominent AQPs in matched NSCLC and normal speci-
mens by quantitative real-time PCR analyses. Addition-
ally, AQP expression was investigated in nine NSCLC
cell lines to identify potential AQP-related intervention
models. The expression of AQP4, yet unknown in
NSCLCs, was further analyzed by immunohistochemis-
try and western blotting.
Methods
Patient population and tissue specimens
All tumors were removed in the Department of Thoracic
Surgery, University Hospital Heidelberg, and diagnoses
were confirmed by at least two experienced pathologist
according to the current WHO classification for lung
cancer [20]. All patients provided appropriate informed
consent. For qRT-PCR analysis, we used a previously
described sample collective of 105 NSCLC and normal
lung tissues including matched tumors and normal tis-
sues from 45 patients [21]. The usage of all tissues for
this study was approved by the local ethics committee
(No. 206/2005).
AQP gene expression analysis by data mining of
independent NSCLC microarray studies
Expression of AQP genes was analyzed using five inde-
pendent microarray studies [22-24,21,25]. The microar-
ray data was downloaded from NCBI GEO database
(GSE10245, GSE8894, GSE3398) or kindly provided upon
request [23,22]. We used only data from AC, SCC, and
normal lung samples. The datasets comprised 576 differ-
ent microarray profiles (Additional file 1, Table S1). First,
pre-processing and the selection of representative
sequences of the AQPs from the four different microar-
ray platforms were performed using Bioconductor and R
as previously described [26]. The datasets were separately
investigated for AQP isoforms gene expression variation
in AC (n = 417), SCC (n = 127), and normal lung tissues
(n = 32). Student’s t-Test was used to analyze differential
expression of distinct AQPs between tumor and normal
samples or between the two subtypes AC and SCC
(Additional file 2, Table S2). A fold change was calculated
by dividing the medians of linear expression values in
each comparison. In the case of different features per
gene, we used the median of the present expression
values.
For AQP4, we determined the overlap of the 100
highest correlated and 100 highest anti-correlated genes
across all microarray datasets ranked by Pearson corre-
lation (Additional file 3, Table S3). The gene signatures
were further examined using Ingenuity Pathways Knowl-
edge Base (Ingenuity, Mountain View, USA), one of the
largest manual curated database, to identify associations
with cellular functions and diseases. Hierarchical cluster-
ing of genes and samples was based on Manhattan dis-
tance measures.
Quantitative real-time PCR
Total RNA was extracted using the RNeasy Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s
instructions. Reverse transcription was performed with 2
μg total RNA per reaction using RevertAid™ First Strand
cDNA Synthesis Kit (Fermentas, Burlington, ON, Canada).
The amount of cDNA equivalent to 5 ng total RNA was
included in each PCR reaction. Expression analysis of five
AQPs (AQP1, -3, -4, -5, -9) and the housekeeping gene
esterase D (ESD) was performed in 105 different tissue
specimens and nine cell lines by quantitative real-time
PCR (ABI Prism 7900HT Sequence Detection System;
Applied Biosystems, Weiterstadt, Germany). The proce-
dure was previously described in detail [21]. Briefly, we
used gene specific primer and probe Taqman assays (ABI)
and performed relative quantification by delta-delta Ct
method using the housekeeping gene esterase. Raw and
processed data are given in Additional file 4, Table S4.
Gene expression differences between sample groups were
analyzed using t-test or paired t-test. BoxPlot presentation
was generated by GraphPad prism, version 2.01 (Graph-
Pad Software, San Diego, CA).
Tissue microarray construction
A tissue microarray (TMA) containing 125 early stage
NSCLC specimens (clinical stage I and II) and the corre-
sponding non-neoplastic lung tissue was constructed
as described previously [27]. Briefly, the TMA contained
tissue samples of 52 AC, 49 SCC, 17 pleomorphic car-
cinomas, 3 basaloid carcinomas, 2 adeno-squamous carci-
nomas, and 2 large cell carcinomas. Prior to TMA
construction a HE-stained slide of each block was analyzed
Warth et al. BMC Cancer 2011, 11:161
http://www.biomedcentral.com/1471-2407/11/161
Page 2 of 9
in order to select the inappropriate regions (e.g. excluding
necrosis, haemorrhage) for the TMA slides. A TMA
machine (AlphaMetrix Biotech, Rödermark, Germany)
was used to extract a 1.6 mm cylindrical core sample from
the tissue donor block.
Immunohistochemistry and statistical analyses
Immunohistochemical staining was performed according
to a standardized protocol using the following primary
antibody: rabbit polyclonal anti-AQP4 against the epi-
tope corresponding to amino acids 244-323 of human
origin (dilution: 1:100; Santa Cruz Biotechnology, Santa
Cruz, CA, USA). The TMA slides were deparaffinized
and pre-treated with an antigen retrieval buffer (pH 6.0;
DAKO, Hamburg, Germany). Subsequent steps were
carried out in an immunostaining device (DAKO Tech-
mate 500plus). The immunostaining protocol was based
on the avidin-biotin peroxidase principle using AEC as
the chromogen, as well as haematoxilin for counter-
staining. As positive controls we used human kidney
sections as a common source of AQP4. For negative
controls, the primary antibody was omitted. For opti-
mized evaluation and scoring the stained TMAs were
scanned with a resolution of 0.25 μm/pixel using a
ScanScope CS System and analyzed using ImageScope
(both Aperio Technologies, Vista, CA, USA).
A semi-quantitative evaluation of the AQP4 immunor-
eactivity was done scoring both the staining intensity (no
staining = 0, weak = 1, moderate = 2, strong = 3) and the
amount of positively stained cells (0 = 0%, 1 = 1-20%, 2 =
21-50%, 3 = 51-80%, 4 = >80%). The multiplied scoring
resulted in an immunoreactivity score (IRS) between 0
and 12. All available survival data from the AC patients
(n = 46) were used for Kaplan-Meier analyses. Mean
post-operative follow-up was 1172 days. At the time
point of this study 31 patients were alive (Additional file
5, Table S5).
Western blotting
For western blotting we selected tumor samples (six ade-
nocarcinomas and one normal lung tissue) with available
fresh frozen tissue. Total protein extracts were prepared
from 5 μm slices of fresh frozen tissue samples. The
slices were crushed for 30 seconds in cell lysis buffer
(Cell Signaling Technology, Boston, USA), centrifuged at
14,000 rpm at 4°C for 10 minutes, and quantified using
the Bradford assay (Bio-Rad Laboratories, München,
Germany). 25 μg of cleared supernatant was diluted in 3×
sample buffer, heated 5 min. at 95°C, loaded onto a 15%
sodium dodecyl sulphate polyacrylamide gel electrophor-
esis (25 μg/lane), and electro-transferred to a polyvinyli-
dene fluoride membrane. The membrane was blocked in
Tris-buffered saline/Tween with 5% milk powder (TBST)
for 1 h. We used the same primary anti-AQP4 antibody
as for immunohistochemistry (1:200; Santa Cruz Biotech-
nology, CA, USA), and anti-actin antibody (1:10000;
Santa Cruz Biotechnology, CA, USA) diluted in TBST
and incubated at 4°C overnight. The appropriate second-
ary antibody was applied (1:2000; horseradish peroxidase
anti-mouse and horseradish peroxidase anti-rabbit) at
room temperature for 1 hour. Visualization was per-
formed by enhanced chemiluminescence (PerkinElmer
Life and Analytical Sciences, Shelton, USA). Blots were
subjected to quantitative analysis using ImageJ software.
The AQP4/actin-ratios are given in densitometry units
under the blots.
Results
Comprehensive AQP expression analyses in NSCLC reveal
a predominant expression of AQP1, -3, and -4 in
adenocarcinomas
We investigated the AQP expression in normal lung and
NSCLC tumor samples and in AC and SCC tumor sub-
types. Gene expression values of AQPs 1-12 were avail-
able in at least two independent datasets (Additional file
2, Table S2). Considering the relative expression level
ranks of AQPs across all present genes in each dataset,
we observed a wide intensity range from low (AQP8, -10,
-11 and -12) to moderate (AQP4, -5, -6 and -7) and high
abundancy (AQP1, -2, -3 and -9). AQP1, -3, -4, -5 and -9
were differentially expressed between tumor and normal
or AC and SCC subtype in at least one microarray data-
set (p-value < 0.05; Fold change ≥ 2 or ≤ 0.5), and there-
fore selected for further qRT-PCR analysis (Table 1). The
expression of the five AQPs could be measured in nearly
all NSCLC and normal lung samples (Additional file 4,
Table S4). Widely consistent with the microarray data
AQP1, -3 and -4 were expressed in a similar range (med-
ian Ct values: 27.8, 26.9, 28.7, respectively), whereas
AQP5 and -9 transcripts were less abundant (median Ct
values: 31.8, 31.0). Furthermore, AQP1 and -4 expression
was highly correlated across the 105 lung cancer and nor-
mal samples (Pearson correlation: 0.82) as previously
observed in the microarray data.
Although a direct comparison is restricted due to dif-
ferences in cellular composition between normal lung
and NSCLC samples, AQP expression levels showed an
overall lower expression of AQP1, -4 and -5 in NSCLC
compared to the respective normal lung tissues of 45
patients (Table 2, Figure 1). Only AQP3 was higher
expressed in AC compared to the normal lung. Further-
more, the microarray data indicated a higher expression
of AQP1, -3, -4 and -5 in AC compared to SCC subtype.
The qRT-PCR results were in agreement with the micro-
array data (except for AQP5) that revealed higher expres-
sion of AQP1, -3 and -4 in AC compared to SCC. All
other AQPs showed very little or no expression differ-
ences in these comparisons.
Warth et al. BMC Cancer 2011, 11:161
http://www.biomedcentral.com/1471-2407/11/161
Page 3 of 9
Comparing expression data of the ACs with follow-up
data indicated a better prognosis when AQP1 (p =
0.0340) and -4 (p = 0.0344) were higher expressed
(Table 2). None of the other AQPs indicated an associa-
tion to prognostic parameters in AC, SCC or both. Of
note, AQP4 showed the strongest transcriptional dereg-
ulation between tumor and normal tissues (fold change:
0.11), the subtypes AC and SCC (6.0) and AC patient
collectives with good and bad survival (4.4), respectively.
AQP4-protein is more abundant in well-differentiated
adenocarcinomas
Since AQP4 expression has not been described previously
in NSCLCs we aimed to further confirm the expression on
the protein level. Anti-AQP4 immunoreactivity was found
in 49 out of 125 NSCLC samples (39.2%). The analyses
confirmed the transcript level that AQP4 protein expres-
sion was almost exclusively present in AC (Figure 2). The
highest expression levels were seen in well-differentiated
ACs, often with bronchioloalveolar and acinar differentia-
tion, whereas poorly differentiated ACs, SCCs and the
other investigated NSCLC subtypes showed no or only
low-level AQP4 expression (Figure 3). Semi-quantitative
analyses of AQP4 expression in ACs resulted in
immunoreactivity scores (IRS) between 0 and 12 with a
median IRS of 3 (Additional file 5, Table S5). There were
no obvious differences between central and peripheral
tumor areas. Western blotting displayed a similar expres-
sion level of the AQP4 isoforms M1 and M23 in AC and
normal lung (Figure 4). AQP4 expression could not be
detected in endothelial cells of pulmonary vessels.
Although Kaplan-Meier survival analyses of the anti-
AQP4 IRS of the AC patients also indicated that AQP4
expression is associated with a better prognosis, the ana-
lyses failed statistical significance (AQP4 absent (IRS 0) vs.
AQP4 present (IRS 1-12): p = 0.153; not shown). Notably,
at the point of this study all AC patients with high AQP4
expression (IRS 9-12; n = 6) were still alive whereas only
~50% of the patients without AQP4 expression (IRS 0; n =
11) were alive (Additional file 5, Table S5). Thus, both the
higher transcript and the protein level of AQP4 indicated
a better prognosis in AC patients.
Analyses of AQP4-coexpressed genes reveal an
association to basic lung functions and respiratory
disorders
Since both the expression and functional effects of AQP4
in NSCLC are unknown, we used five independent
Table 1 Five AQPs were identified to be deregulated (* p-value < 0.05; Fold change ≥ 2 or ≤ 0.5) in tumors versus
normal tissues, or in AC versus SCC subtype across different microarray studies
AQP
isoform













AQP1 AQP3 AQP4 AQP5
AQP1 0.18* 7.5* 0.22* 2.36* 27.8 X x x x
AQP3 1.00 4.8* 0.93 5.81* 26.9 0.46 x x x
AQP4 0.16* 2.8* 0.11* 5.96* 28.7 0.82 0.42 x x
AQP5 0.94 6.9* 0.50* 1.88 31.8 0.31 0.40 0.24 x
AQP9 0.26* 0.91 1.05 0.64 31.0 0.39 0.34 0.30 0.10
The results were mainly confirmed by qRT-PCR including information about expression range in all tissues and Pearson correlation between different AQPs.
AQP: aquaporin; AC: adenocarcinoma; SCC: squamous cell carcinoma; fold change was calculated across microarray datasets (median); fold change in bold and
marked (*) indicates statistical significance (p-value < 0.05).























AQP1 0.0000 0.22 0.0228 2.36 0.0000 0.26 0.0000 0.10 0.0340 2.86
AQP3 0.7089 0.93 0.0005 5.81 0.0205 1.76 0.0676 0.38 0.7165 0.81
AQP4 0.0000 0.11 0.0144 5.96 0.0000 0.12 0.0002 0.02 0.0344 4.42
AQP5 0.0253 0.50 0.3255 1.88 0.1640 0.55 0.1956 0.39 0.1937 0.25
AQP9 0.7384 1.05 0.1310 0.64 0.6103 0.91 0.7887 1.12 0.7480 1.15
Student’s T-Test comparison between matched tumor (MT) and normal lung tissue (MN) collectives (n = 45), different histology (AC vs SCC) and survival (good
>3 y, bad <3 y).
AQP: aquaporin; AC: adenocarcinoma; SCC: squamous cell carcinoma; p-value and fold change in bold indicate statistical significance.
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microarray datasets to identify potential gene-gene inter-
actions and common biological processes correlated to
AQP4 expression. The analysis of 593 non-redundant
(out of 1000 best ranked) genes resulted in 140 genes
(24%), which were present in at least two independent
datasets (Additional file 3, Table S3). Concerning the fact
that four different microarray platforms and three differ-
ent specimen groups (AC, SCC, normal) were integrated
we concluded a good concordance in this correlation
analysis. The visualization of commonly AQP4-associated
genes in one dataset [21] revealed upregulation of these
genes mainly in an AC subgroup (Figure 5A), which was
in agreement with the qRT-PCR results. Data mining of
the gene set for the potential relevant functions and cor-
relating diseases revealed major associations of AQP4 to
cancer and respiratory disease, as well as links to biologi-
cal processes like cell cycle regulation, lipid metabolism,
cellular movement and cell-to-cell signalling (Table 3).
Many of these genes were involved in specific lung func-
tions like the maintenance of pulmonary surfactant, sur-
face tension, and homeostasis (e.g. pulmonary-associated
surfactant protein family). A subset of genes co-expressed
with AQP4 and associated to respiratory disease were
assigned to potential anti-tumorigenic function like
CAV1 [28], EDNRB [29], or SELENBP1 [30], whereas
Figure 1 Differential gene expression of distinct AQPs in NSCLC. Gene expression of AQP1, -3, -4 and -5 in AC (n = 40), SCC (n = 16) and
normal normal lung tissues (n = 49) including matched cases (n = 45) using qRT-PCR data. T-test results and fold changes for all comparisons
are given in Table 2.
Figure 2 Immunohistochemical analysis of AQP4 expression in
125 NSCLC specimens. Adenocarcinoma (AC), Squamous Cell
Carcinoma (SCC), Pleomorphic Carcinoma (PC), Adeno-Squamous
Carcinoma (ASC), Basaloid Carcinoma (BC), Large Cell Carcinoma (LCA).
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genes more related to pro-tumorigenic function like
CDK2 [31], FOXM1 [32], PLK1 [33] or RRM1 [34] were
found to be anti-correlated with AQP4 (Figure 5B). Thus,
data mining of AQP4-coexpressed genes indicated
important physiological and anti-tumorigenic functions
in both the normal and tumor cells.
Discussion
In the present study we provide a comprehensive over-
view of AQP expression in both normal lung and
NSCLC specimens in order to determine potentially
relevant AQPs for novel anti-cancer therapies. The ana-
lysis of 576 different microarray profiles from normal
lung, AC and SCC and immunohistochemical data
revealed abundant and most variable expression patterns
for AQP1, -3, -4, and -5. Concerning the presence in
normal lung tissues, our expression data of distinct
AQP isoforms based on transcriptomic data were in
agreement with previous protein data [13]. If AQPs
were present in NSCLC, the expression was mainly
increased in ACs (AQP1, -3 and -4). For AQP1 [14,15]
and -3 [17] higher protein expression in AC compared
to SCC has already been described and AQP3 was
found to be predominantly expressed in better differen-
tiated AC [17].
For the first time, we identified AQP4 expression (iso-
forms M1 and M23) in NSCLCs, especially in well dif-
ferentiated ACs, which has not been described before.
Expression was almost exclusively derived from AC
cells. Minor expression of AQP4 mRNA detected in
SCC was at least due to the remaining intra-tumoral
alveolar cells as shown by IHC. Of note, higher expres-
sion of AQP4 in AC was associated to a better outcome
and a similar trend was seen in Kaplan-Meier survival
analyses based on the protein expression data. Data
mining of co-expressed and anti-correlated genes
depicted the association of AQP4 to physiological func-
tions in normal lung tissue which may be progressively
lost during tumor dedifferentiation. A subsequent loss
of AQP4 during carcinogenesis is also described in gas-
tric cancer and AQP4 was therefore suggested to be
used as a marker for normal proliferating gastric cells
[35]. In addition, high AQP4 expression levels are also
detectable in well-differentiated low-grade gliomas [27]
and there is indication that only the expression of
AQP1 enhanced cell growth and migration of gliomas,
while AQP4 expression enhanced cell adhesion [36].
Thus, also AQP4 expression was investigated in various
tumor entities, a significant pro-tumorigenic effect of
this channel could not be identified so far. Since AQP4
expression could not be detected in endothelial cells this
channel does not seem to play a role in tumor-asso-
ciated edema formation and resolution. Yet, only AQP1
expression was identified in pulmonary endothelial cells
and seems to facilitate hydostatically driven edema but
was found not to be required for active near-isosmolar
absorption of alveolar fluid under experimental condi-
tions [37].
Previously, AQP1 [15], -3 [17], and -5 [18] have been
suggested to be involved in NSCLC pathogenesis and
pro-tumorigenic functions have been reported for AQP1
and AQP5 based on in vitro overexpression studies
[15,18]. In our study, AQP4 expression can be assigned
to physiological pulmonary functions and does not
negatively correlate with the survival of NSCLC patients.
Of note, a strong correlation between AQP1 and AQP4
expression was observed across more than 600 different
lung specimens that indicate functional relations
Figure 3 AQP4-protein expression pattern in NSCLCs. AQP4 is
mainly expressed in well differentiated AC (A), and to a lower
extent in moderately differentiated AC (B). SCC are mostly
negative for AQP4, but have AQP4-positive intra-tumoral alveolar
cells (C). D shows AQP4 expression in a pleomorphic carcinoma.
Magnification ×20.
Figure 4 Western blot analyses of AQP4 in normal lung and
adenocarcinomas. This western blot clearly demonstrates the
expression of both the M1 (34 kDa) and the array-forming M23
variant (31 kDa) of AQP4 in normal lung (N) and adenocarcinomas
(AC).
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between both AQPs. This may also question sole pro-
tumorigenic function of AQP1 in the human lung. An
explanation may be that the long-term downregulation
of AQPs in dedifferentiated tumor cells is the conse-
quence of altered water and ion homeostasis or even an
adaption mechanism against apoptosis, which is asso-
ciated with low AQP expression levels [3], whereas over-
expression of single AQPs in tumor cells may promote
oncogenic functions such as cell migration, thereby con-
tributing to tumor progression. Few in-vivo studies in
other cancer entities demonstrated that targeted gene
disruption of AQPs slows down cancer progression [7]
or even prevents tumor formation [5]. Therefore, AQPs
have been recognized as promising targets for novel
anti-cancer therapies [12,38]. For NSCLC, AQP5 may be
the most interesting candidate for novel anti-cancer
therapies [18,19].
Conclusions
In summary, we provide a basis to consider specific
AQPs as potential drug targets in NSCLC. Notably, high
AQP4 expression was found in pulmonary AC with
Figure 5 AQP4-associated gene signature in NSCLC. Supervised clustering of a gene set commonly correlated or anti-correlated to AQP4
gene expression indicates stronger expression in an AC subset (A). Several genes were annotated to be associated with respiratory disease by
using Ingenuity software. Median correlation coefficient (CC) across independent microarray datasets was given for every gene (B).
Table 3 Data mining of AQP4-correlated genes across five independent microarray datasets using commercial
pathway database (Ingenuity Pathway Analysis)
Relevant Functions and Diseases No. of genes Examples (Gene Symbol)
Cancer 65 CALCRL, CDC2, CDH5, DMBT1, EZH2, FABP4, FOLR1, ROS1, THBS2
Respiratory Disease 25 ANGPT1, BUB1B, CAV1, EDNRB, PLK1, RRM1, TGFBR2, TOP2A, VWF
Cell Cycle 17 BUB1B, CDC45L, CDKN3, CENPF, CITED2, MYBL2, PTTG1, RPS6KA2
Lipid Metabolism 15 CAT, CAV1, CYP27A1, FABP4, LPL, SEPP1, SFTPA1, SFTPB, SFTPC, SFTPD
Molecular Transport 17 ABCA3, AGTR2, AQP1, CFD, CYP27A1 NME1
Small Molecule Biochemistry 30 A2M, AOC3, C7, CAT, DIO2, GPX3, LPL, NPR1, PFN2, SEPP1, TEK, TK1
Cellular Movement 35 CAT, CTSE, DLC1, ESAM, ICAM2, PLA2G1B, S1PR1, SFTPC, SFTPD, VIPR1
Cell-to-Cell Signalling 30 C4BPA, COL4A3, DPYSL2, PTPRB, SLC6A4, SULF1, THY1, TROAP
Annotation of 140 commonly AQP4-associated genes revealed strong associations to cancer and pulmonary functions. All entries obtained significant p-value <
0.05. Examples of genes from the input list were given for each function and disease ontology. Detailed information is given in Supplementary Table 3.
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higher differentiation and better prognosis, which chal-
lenges the therapeutic usage of this channel in particu-
lar. Our findings underline the importance to specify
the potential functions of AQPs beyond water transport
both in normal tissue and tumor cells.
Additional material
Additional file 1: Table S1. Integrated microarray datasets. Overview
about all integrated microarray datasets including references, microarray
platform information, number of NSCLC (AC, SCC) and normal lung
samples, and possible comparisons conducted in the expression analysis
of aquaporins.
Additional file 2: Table S2. AQP gene expression patterns across
five different microarray datasets. AQPs were analyzed by comparing
different sample sets like tumor (Tu) and normal (No) tissues as well as
tumor subtypes adenocarcinoma (AC) and squamous cell carcinoma
(SCC) including representative microarray features, p-value (Student’s t-
Test) and fold change in every dataset. The values in bold indicate
significantly differential expression (p-value < 0.05; Fold change > 2 or <
0.5). Fields marked by a cross means that the AQP is not present in the
dataset or the comparison could not performed because of absence of
distinct sample sets. Relative expression values of all AQP isoforms were
ranked in dependence all present genes in each dataset, and the median
value across all datasets indicates that a certain AQP is stronger
expressed than a defined proportion (%) of all other genes.
Additional file 3: Table S3. AQP4 co-expressed and anti-correlated
genes across five independent microarray datasets. AQP4 co-
expressed and anti-correlated genes across five independent microarray
datasets measured by Pearson correlation. In total 593 non-redundant
genes (out of 200 best ranked features of each microarray dataset) were
extracted and ranked by the presence frequency (No. of datasets) and
the median correlation coefficiency (CC) across different datasets. Genes
included in at least two independent datasets were assigned to
prominent cellular functions or diseases by Ingenuity Pathway Database
software.
Additional file 4: Table S4. Validation data of AQP expression in
normal lung and NSCLC by qRT-PCR. The qRT-PCR (Taqman) data of
normal lung (N) and NSCLC tumor (T) tissues are presented according to
the delta-delta Ct method including raw data (Ct values and MAD error),
normalized data by ESD housekeeping gene (dCt value and error) and
expression values (ddCt, ddCt error, expression level, level error) relative
to the median of the normal lung samples. In the case of the different
lung cancer cell lines expression values are assigned relative to A549 cell
line. Taqman assays of AQP and ESD genes are specified by gene
symbol, assay ID and representative sequence.
Additional file 5: Table S5. Clinicopathologic data of the tissue
microarray specimens. Patient data including survival status, follow-up,
AQP4 immunoreactivity score (IRS) and tumor staging.
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